STUTTGART, Germany I December 11, 2019 I La Merie Publishing announced the release of its newest report “Competitor Analysis: Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More”.
The competitive intelligence report about Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More evaluates the landscape of the next wave of investigational antibodies in development as biosimilars of marketed antibodies in regulated and less regulated markets as of December 2019.
Cancer antibodies Avastin, Herceptin and Rituxan/MabThera and anti-TNF antibodies Remicade, Enbrel and Humira were the targets of the first wave of biosimilar antibody developments. With the approval and launch of first wave biosimilar antibodies in regulated and less regulated markets, biosimilar antibody developers and manufacturers have directed their business activity towards the next wave of possible biosimilar antibodies.
The coming wave of patent expiries and loss of market exclusivity in the US and in the European Union has spurred the development of biosimilar antibodies for ophthalmic, metabolic, anti-inflammatory and anti-autoimmune antibodies. While developers in regulated markets focus their activity on those marketed antibodies with patent expiration and loss of market protection until 2025, developers for less regulated markets are already looking beyond the year 2025.
This report evaluates the competitive situation of biosimilar antibody developments in regulated and less regulated markets including
- Lucentis
- Eylea
- Prolia/XGEVA
- Xolair
- Stelara
- Soliris
- Erbitux
- Perjeta
- Synagis
- Yervoy
- Cimzia
- (Ro)Actemra
- Simponi
- Orencia
- Tysabri
- Ilaris
- Opdivo
- Keytruda
- Tecentriq
- Cyramza
- Cosentyx
- Darzalex
- Entyvio
The report provides an overview of the year of the first approval in the US and the EU and global sales in 2018 of these marketed antibodies.
The report can be acquired at La Merie Publishing’s online store at https://lamerie.com/report/next-wave-biosimilar-antibodies-of-lucentis-eylea-xolair-prolia-stelara-soliris-and-more/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports as well as competitor analysis reports and target pipeline lists, the latter two in a tabulated format with structured listings of industry-relevant data. La Merie Publishing products can be purchased in our new online store at www.lamerie.com and at selected Resellers.
The focus of our products is directed towards therapeutic biologics, such as antibodies, proteins, peptides, vaccines and gene & cell therapy. We pay special attention to biosimilar antibodies and proteins, antibody drug conjugates, bispecific antibodies, TCR & CAR engineered antibodies, mRNA vaccines & therapeutics, oncolytic viruses and immuno-oncology in general.
To leverage our expertise and knowledge accumulated in our in-house database, we offer custom report preparation services for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest for our clients.
SOURCE: La Merie Publishing
Post Views: 30
STUTTGART, Germany I December 11, 2019 I La Merie Publishing announced the release of its newest report “Competitor Analysis: Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More”.
The competitive intelligence report about Next Wave Biosimilar Antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More evaluates the landscape of the next wave of investigational antibodies in development as biosimilars of marketed antibodies in regulated and less regulated markets as of December 2019.
Cancer antibodies Avastin, Herceptin and Rituxan/MabThera and anti-TNF antibodies Remicade, Enbrel and Humira were the targets of the first wave of biosimilar antibody developments. With the approval and launch of first wave biosimilar antibodies in regulated and less regulated markets, biosimilar antibody developers and manufacturers have directed their business activity towards the next wave of possible biosimilar antibodies.
The coming wave of patent expiries and loss of market exclusivity in the US and in the European Union has spurred the development of biosimilar antibodies for ophthalmic, metabolic, anti-inflammatory and anti-autoimmune antibodies. While developers in regulated markets focus their activity on those marketed antibodies with patent expiration and loss of market protection until 2025, developers for less regulated markets are already looking beyond the year 2025.
This report evaluates the competitive situation of biosimilar antibody developments in regulated and less regulated markets including
- Lucentis
- Eylea
- Prolia/XGEVA
- Xolair
- Stelara
- Soliris
- Erbitux
- Perjeta
- Synagis
- Yervoy
- Cimzia
- (Ro)Actemra
- Simponi
- Orencia
- Tysabri
- Ilaris
- Opdivo
- Keytruda
- Tecentriq
- Cyramza
- Cosentyx
- Darzalex
- Entyvio
The report provides an overview of the year of the first approval in the US and the EU and global sales in 2018 of these marketed antibodies.
The report can be acquired at La Merie Publishing’s online store at https://lamerie.com/report/next-wave-biosimilar-antibodies-of-lucentis-eylea-xolair-prolia-stelara-soliris-and-more/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports as well as competitor analysis reports and target pipeline lists, the latter two in a tabulated format with structured listings of industry-relevant data. La Merie Publishing products can be purchased in our new online store at www.lamerie.com and at selected Resellers.
The focus of our products is directed towards therapeutic biologics, such as antibodies, proteins, peptides, vaccines and gene & cell therapy. We pay special attention to biosimilar antibodies and proteins, antibody drug conjugates, bispecific antibodies, TCR & CAR engineered antibodies, mRNA vaccines & therapeutics, oncolytic viruses and immuno-oncology in general.
To leverage our expertise and knowledge accumulated in our in-house database, we offer custom report preparation services for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest for our clients.
SOURCE: La Merie Publishing
Post Views: 30
